Quality of Life and the Experience of Living with Early-Stage Alzheimer's Disease

Background: There is a need to better understand the experience of patients living with Alzheimer's disease (AD) in the early stages. Objective: The aim of the study was to evaluate the perception of quality of life in patients with early-stage AD. Methods: A multicenter, non-interventional study wa...

Full description

Bibliographic Details
Authors: Villarejo-Galende, A; Garcia-Arcelay, E; Pinol-Ripoll, G; del Olmo-Rodriguez, A; Vinuela, F; Boada, M; Franco-Macias, E; de la Pena, AI; Riverol, M; Puig-Pijoan, A; Abizanda-Soler, P; Arroyo, R; Baquero-Toledo, M; Feria-Vilar, I; Balasa, M; Berbel, A; Rodriguez-Rodriguez, E; Vieira-Camposs, A; Garcia-Ribas, G; Rodrigo-Herrero, S; Terrancle, A; Prefasi, D; Lleo, A; Maurino, J
Format: Article
Status:Published version
Publication date:2022
Country:España
Institution:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repository:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:fisabio.fundanetsuite.com:p14313
Online Access:https://fisabio.portalinvestigacion.com/publicaciones/14313
Access Level:Open access
Keyword:Alzheimer's disease
depression
early-stage
hopelessness
quality of life
stigma
Description
Summary:Background: There is a need to better understand the experience of patients living with Alzheimer's disease (AD) in the early stages. Objective: The aim of the study was to evaluate the perception of quality of life in patients with early-stage AD. Methods: A multicenter, non-interventional study was conducted including patients of 50-90 years of age with prodromal or mild AD, a Mini-Mental State Examination (MMSE) score >= 22, and a Clinical Dementia Rating-Global score (CDR-GS) of 0.5-1.0. The Quality of Life in Alzheimer ' s Disease (QoL-AD) questionnaire was used to assess health-related quality of life. A battery of self-report instruments was used to evaluate different psychological and behavioral domains. Associations between the QoL-AD and other outcome measures were analyzed using Spearman's rank correlations. Results: A total of 149 patients were included. Mean age (SD) was 72.3 (7.0) years and mean disease duration was 1.4 (1.8) years. Mean MMSE score was 24.6 (2.1). The mean QoL-AD score was 37.9 (4.5). Eighty-three percent (n = 124) of patients had moderate-to-severe hopelessness, 22.1% (n = 33) had depressive symptoms, and 36.9% (n = 55) felt stigmatized. The quality of life showed a significant positive correlation with self-efficacy and negative correlations with depression, emotional and practical consequences, stigma, and hopelessness. Conclusion: Stigma, depressive symptoms, and hopelessness are frequent scenarios in AD negatively impacting quality of life, even in a population with short disease duration and minimal cognitive impairment.